Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Current Deferred Revenue (2016 - 2018)

Altimmune (ALT) has disclosed Current Deferred Revenue for 7 consecutive years, with $173952.0 as the latest value for Q3 2018.

  • Quarterly Current Deferred Revenue rose 833.92% to $173952.0 in Q3 2018 from the year-ago period, while the trailing twelve-month figure was $173952.0 through Sep 2018, up 833.92% year-over-year, with the annual reading at $19753.0 for FY2017, 0.0% changed from the prior year.
  • Current Deferred Revenue for Q3 2018 was $173952.0 at Altimmune, up from $32253.0 in the prior quarter.
  • The five-year high for Current Deferred Revenue was $173952.0 in Q3 2018, with the low at $18626.0 in Q3 2017.
  • Average Current Deferred Revenue over 4 years is $47279.5, with a median of $26003.0 recorded in 2016.
  • The sharpest move saw Current Deferred Revenue crashed 92.88% in 2014, then skyrocketed 833.92% in 2018.
  • Over 4 years, Current Deferred Revenue stood at $62261.0 in 2014, then crashed by 68.27% to $19753.0 in 2016, then changed by 0.0% to $19753.0 in 2017, then skyrocketed by 780.64% to $173952.0 in 2018.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $173952.0, $32253.0, and $19385.0 for Q3 2018, Q2 2018, and Q1 2018 respectively.